(12) United States Patent (10) Patent No.: US 9,539,217 B2 Sosin Et Al
Total Page:16
File Type:pdf, Size:1020Kb
USO09539217B2 (12) United States Patent (10) Patent No.: US 9,539,217 B2 Sosin et al. (45) Date of Patent: Jan. 10, 2017 (54) NANOPARTICLE COMPOSITIONS (56) References Cited (71) Applicant: ALLERTEIN THERAPEUTICS, U.S. PATENT DOCUMENTS LLC, Fairfield, CT (US) 3,977,794. A 8/1976 Liedholz 4,191,743 A 3, 1980 Klemm et al. (72) Inventors: Howard Sosin, Southport, CT (US); 4,270,537 A 6, 1981 Romaine Michael Caplan, Woodbridge, CT 4,316,885. A 2f1982 Rakhit (US); Tarek Fahmy, Fairfield, CT (US) 4,384,996 A 5/1983 Bollinger et al. 4,596,556 A 6, 1986 Morrow et al. (73) Assignee: Allertein Therapeutics, LLC, Fairfield, SS s 38. Stet al. CT (US) 4,790,824. A 12/1988 Morrow et al. 4,798,823. A 1, 1989 Witzel (*) Notice: Subject to any disclaimer, the term of this 4,886,499 A 12/1989 Cirelli et al. patent is extended or adjusted under 35 is: A 3. thatara et al.al U.S.C. 154(b) by 0 days. 4.940,460 A 7/1990 Casey et al. 4.941,880 A 7, 1990 Burns (21) Appl. No.: 14/782.285 4.956,352. A 9/1990 Okuhara et al. 5,008, 110 A 4, 1991 Benecke et al. 22) PCT Fed: Apr.p 3, 2014 5,015,235 A 5/1991 Crossman 5,064,413 A 11/1991 McKinnon et al. (86). PCT No.: PCT/US2O14/O32838 (Continued) S 371 (c)(1), FOREIGN PATENT DOCUMENTS (2) Date: Oct. 2, 2015 EP 1752151 A1 2, 2007 (87) PCT Pub. No.: WO2014/165679 WO WO-92,051.79 A1 4f1992 PCT Pub. Date: Oct. 9, 2014 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2016/O113881 A1 Apr. 28, 2016 Aguado et al., Controlled release vaccines biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles, Immunobiology, 184(2-3): 113-25 (1992). Related U.S. Application Data Anderson and Shive, et al., Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv Drug Deliv Rev. 28(1):5-24 (60) Provisional application No. 61/808,118, filed on Apr. (1997). 3, 2013. Apostolopoulos, V. et al., Structural implications for the design of molecular vaccines, Curr. Opin. Mol. Ther. 2(1): 29-36 (2000). (51) Int. Cl. Aziz et al., Oral Vaccines: New Needs, New Possibilities, BioEs A6 IK 9/14 (2006.01) BlanchetteR R. et Ea.al., Cellular evaluation offoral oral chemotherapychemoth carriers, A6 IK 9/16 (2006.01) J. Biomed. Mater. Res. A., 72(4): 381-388 (2005). A 6LX 9/50 (2006.01) B1anchette et al., Oral chemotherapeutic delivery: designas and cel A 6LX 39/35 (2006.01) lular response, Ann. Biomed. Eng., 33(2): 142-149 (2005). A 6LX 9/5 (2006.01) (Continued) A6 IK 39/02 (2006.01) A6 IK 39/45 (2006.01) Primary Examiner — Robert A Wax A 6LX 39/39 (2006.01) Assistant Examiner — Quanglong Truong CI2N 7/00 (2006.01) (74) Attorney, Agent, or Firm — Brenda Herschbach A61 K 39/00 (2006.01) Jarrell; Brian E. Reese; Choate, Hall & Stewart LLP (52) U.S. Cl. CPC ........... A6IK 9/5031 (2013.01); A61K 9/5153 (57) ABSTRACT (2013.01); A61K 39/025 (2013.01); A61 K The present invention provides, among other things, nano 39/145 (2013.01); A61K 39/35 (2013.01); particle compositions including a plurality of nanoparticles, A61K 39/39 (2013.01): CI2N 7/00 (2013.01); each of which is comprised of a biodegradable O biocom A61K 2039/5258 (2013.01); A61 K 2039/54 patible polymer arranged in a nanoparticle structure defining (2013.01); A6 IK 2039/542 (2013.01); A61 K an internal lumen and an external Surface and one or more 2039/545 (2013.01); A61 K 2039/555 II of a preparation of hydrophilic cellular components and a (2013.01); A61 K 2039/55516 (2013.01); A61 K preparation of hydrophobic cellular components. In some 2039/55555 (2013.01); A61 K 2039/55561 embodiments, the preparation of hydrophilic cellular com (2013.01); A61 K 2039/55566 (2013.01); A61 K ponents is encapsulated within the internal lumen and the 2039/57 (2013.01); C12N 2760/16034 preparation of hydrophobic cellular components is associ s (2013.01) ated with the external surface. Various methods of making (58) Field of Classification Search and using disclosed nanoparticle compositions are also None provided. See application file for complete search history. 20 Claims, 29 Drawing Sheets US 9,539,217 B2 Page 2 (56) References Cited 7.534449 B2 5/2009 Saltzman et al. 7.550,154 B2 6/2009 Saltzman et al. U.S. PATENT DOCUMENTS 8,802.375 B2 8/2014 Sampson et al. 8,815,251 B2 8/2014 Caplan et al. 5,100,883. A 3, 1992 Schiehser 8,889,117 B2 11/2014 Mellman et al. 5,118,678 A 6, 1992 Kao et al. 2001/005.1155 A1 12/2001 Sosin et al. 5, 120,725 A 6, 1992 Kao et al. 2002fOOO9452 A1 1/2002 Caplan 5, 120,727 A 6, 1992 Kao et al. 2002fOO44959 A1 4/2002 Goetz et al. 5,120,842 A 6, 1992 Failli et al. 2002/0076420 A1 6/2002 Caplan et al. 5, 122,511 A 6, 1992 Patchett et al. 2002/0132763 A1 9, 2002 Naicker et al. 5,141.496 A 8, 1992 Dalto et al. 2002fO155607 A1 10, 2002 Boutin 5,143,918 A 9, 1992 Bochis et al. 2003,0003591 A1 1/2003 LaCourt et al. 5,151,413 A 9, 1992 Caufield et al. 2003/0035.810 A1 2/2003 Caplan 5,162,334 A 11/1992 Goulet et al. 2003/0202980 A1 10/2003 Caplan et al. 5,169,851 A 12/1992 Hughes et al. 2003/0235619 A1 12/2003 Allen et al. 5,189,042 A 2f1993 Goulet et al. 2004/002284.0 A1 2/2004 Nagy et al. 5, 190,521 A 3, 1993 Hubbard et al. 2004/OO23897 A1 2/2004 Caplan 5,202,332 A 4/1993 Hughes et al. 2004/O156821 A1 8/2004 Bottomly et al. 5,208,228 A 5, 1993 Ok et al. 2004/0208894 A1 10/2004 Caplan 5,208,241 A 5, 1993 Ok et al. 2004/0234548 A1 11/2004 Caplan 5,225, 194 A 7, 1993 Suer 2006,0002852 A1 1/2006 Saltzman et al. 5,227.467 A 7, 1993 Durette et al. 2006,0002971 A1 1/2006 Saltzman et al. 5,250,678 A 10, 1993 Goulet et al. 2006, OO51426 A1 3/2006 Golomb et al. 5,254,562 A 10, 1993 Okuhara et al. 2006, OO77390 A1 4/2006 Kralik 5,258,389 A 1 1/1993 Goulet et al. 2006, OO87650 A1 4, 2006 Shen 5,262,533 A 1 1/1993 Sinclair et al. 2006.0109468 A1 5.2006 Evans 5,284.826 A 2, 1994 Eberle 2006/0246139 A1 11/2006 Miyaji et al. 5,284,840 A 2/1994 Rupprecht et al. 2007/0092575 A1 4/2007 Balaban et al. 5,312,335 A 5, 1994 McKinnon et al. 2007/0148074 A1 6/2007 Sadoqi et al. 5,328,483. A 7/1994 Jacoby 2007. O184068 A1 8, 2007 Renner et al. 5,334,144 A 8, 1994 Alchas et al. 2007/0213507 A1 9, 2007 Burks et al. 5,339,163 A 8, 1994 Homma et al. 2007/0224225 A1 9, 2007 Irache Garreta et al. 5,383,851 A 1/1995 McKinnon, Jr. et al. 2008.0014144 A1 1/2008 Saltzman et al. 5,417,662 A 5/1995 Hjertman et al. 2008/0249014 A1* 10, 2008 Tauer ....................... CO7K 1.36 5,466,220 A 11/1995 Brenneman 514f172 5,480,381 A 1/1996 Weston 2009 OO11993 A1 1/2009 Murthy et al. 5,503,627 A 4, 1996 McKinnon et al. 2009 O239789 A1 9/2009 Saltzman et al. 5,504.091 A 4, 1996 Molnar-Kimber et al. 2009,0269.397 A1 10, 2009 Saltzman et al. 5,520,639 A 5, 1996 Peterson et al. 2010, OO31262 A1 2/2010 Baird-Gent 5,527,288 A 6, 1996 Gross et al. 2010, 0104503 A1 4/2010 Mellman et al. 5,532,248 A 7, 1996 Goulet et al. 2010, O151436 A1 6/2010 Fong et al. 5,543,158 A 8, 1996 Gref et al. 2010, 01668O2 A1 7/2010 Caplan et al. 5,558,869 A 9/1996 Burks, Jr. et al. 2010. 0233251 A1 9/2010 Von Andrian ......... A61K 39.00 5,569,189 A 10, 1996 Parsons 424/450 5,591,767 A 1/1997 Mohr et al. 2010/0284965 A1 11/2010 Fahmy et al. 5,599,302 A 2/1997 Lilley et al. 2011/0027298 A1 2/2011 Caplan et al. 5,649,912 A 7, 1997 Peterson 2011/0218396 A1 9, 2011 Williams et al. 5,683,712 A 11/1997 Cavazza 2011/0293705 A1 12/2011 Irvine et al. 5,693,648 A 12/1997 Goulet et al. 2012/0276.156 A1 11/2012 Fraser et al. 5,704,911 A 1/1998 Parsons 2013/0302409 A1 11/2013 Fuchs et al. 5,709,797 A 1/1998 Bocchiola et al. 2015.0118318 A1 4/2015 Fahmy et al. 5,739,432 A 4, 1998 Sinha 2015, 0125384 A1 5, 2015 Mellman et al. 5,753,234. A 5, 1998 Lee et al. 2015. O153358 A1 6/2015 Ayuso et al. 5,774,209 A 6, 1998 SheStock 2015,01742.25 A1 6/2015 Caplan 5,830,877 A 11/1998 Carson et al.